Strontium ranelate

JK Science

Volumn 8, Issue 2, 2006, Pages 114-115

  Tandon, Vishal R ^a   Sharma, Sudhaa ^a   Mahajan, A Annil ^a   Parihar, A ^a   Singh, Kulbir ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATINE KINASE; PARATHYROID HORMONE[1-34]; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE;

BONE DENSITY; BONE TURNOVER; CELL ACTIVITY; CELL DIFFERENTIATION; CELL DIVISION; CLINICAL TRIAL; COLLAGEN SYNTHESIS; DIARRHEA; ENZYME ACTIVITY; FEMUR NECK; HIGH RISK PATIENT; HUMAN; INCIDENCE; LONG TERM CARE; LUMBAR SPINE; LUNG EMBOLISM; MENTAL DISEASE; META ANALYSIS; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOMALACIA; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 33746704922     PISSN: 09721177     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Sharma S, Tandon V, Mahajan A. Therapeutic strategies for postmenopausal osteoporosis: Present and future. Obs & Gynae Today 2004; 9(11): 758-62.
2. Burlet N, Reginster JY. Strontium Ranelate: The First Dual Acting Treatment for Postmenopausal Osteoporosis. Clin Orthop Relat Res 2006; 443: 55-60
3. Dimai HP.Strontium ranelate: a novel concept for the treatment of osteoporosis] Wien Klin Wochenschr 2005; 117(21-22): 728-38.
4. Marie PJ. Strontium ranelate: A physiological approach for optimizing bone formation and resorption. Bone 2006 Jan 23; [ahead of print]
5. Reginster JY, Spector T, Badurski J et al. A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium nanelate phase III program. Osteoporos Int 2002; 13: S30.
6. Reginster JY, Deroisy R, Dougados M et al. Prevention of early postmenopausal bone loss by strontium ranelate: a randomized two-year, double-blind, dose-ranging, placebo-controlled trial. Osteoporosis Int 2002; 13: 925-31.
7. Reginster JY, Meunier PJ. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int 2003;14 (Suppl 3): S56-65.
8. Meunier PJ, Roux C, Seeman E, Ortolani S, The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350(5): 459-68.
9. Adami S. Protelos: Nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis. Bone 2006 Jan 21; [ahead of print]
10. Ortolani S, Vai S. Strontium ranelate: An increased bone quality leading to vertebral antifracture efficacy at all stages. Bone 2006; 38(2 Suppl 1): 19-22.
11. [No authors listed]. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns. Prescrire Int 2005; 14(80): 207-11.